883876-21-9

Basic information

• Product Name: 2,5-DIBROMO-1H-IMIDAZOLE-4-CARBOXYLIC ACID METHYL ESTER
• Synonyms: 2,5-DIBROMO-1H-IMIDAZOLE-4-CARBOXYLIC ACID METHYL ESTER;methyl 2,5-dibromo-1H-imidazole-4-carboxylate;1H-Imidazole-4-carboxylic acid,2,5-dibromo-,methyl ester
• CAS NO: 883876-21-9
• Molecular Formula: C5H4Br2N2O2
• Molecular Weight: 283.90546
• Mol File: 883876-21-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 2,5-DIBROMO-1H-IMIDAZOLE-4-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-DIBROMO-1H-IMIDAZOLE-4-CARBOXYLIC ACID METHYL ESTER(883876-21-9)
• EPA Substance Registry System: 2,5-DIBROMO-1H-IMIDAZOLE-4-CARBOXYLIC ACID METHYL ESTER(883876-21-9)

Safety Data

• Hazardous Substances Data: 883876-21-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2,5-DIBROMO-1H-IMIDAZOLE-4-CARBOXYLIC ACID METHYL ESTER is used as a key intermediate in the synthesis of various pharmaceuticals, agrochemicals, and other fine chemicals. Its unique structure and reactivity make it a valuable component in the development of new and innovative compounds with diverse applications.
Used in Antimicrobial and Antifungal Applications:
2,5-DIBROMO-1H-IMIDAZOLE-4-CARBOXYLIC ACID METHYL ESTER exhibits antimicrobial and antifungal properties, making it a useful ingredient in the development of new medications and pesticides. Its ability to inhibit the growth of harmful microorganisms and fungi can contribute to the creation of more effective treatments and preventive measures against infections and diseases.
Used in Anti-inflammatory and Antitumor Research:
2,5-DIBROMO-1H-IMIDAZOLE-4-CARBOXYLIC ACID METHYL ESTER has shown potential as an anti-inflammatory and antitumor agent in preliminary research. Its ability to modulate inflammatory responses and inhibit tumor growth makes it a subject of interest for further pharmacological studies. 2,5-DIBROMO-1H-IMIDAZOLE-4-CARBOXYLIC ACID METHYL ESTER may lead to the development of novel therapeutic agents for the treatment of various inflammatory and neoplastic conditions.

Upstream product

• 17325-26-7 Methyl imidazole-4-carboxylate 

Relevant articles and documents

Structure-activity relationship (SAR) investigations of substituted imidazole analogs as TRPV1 antagonists

A novel series of 4,5-biarylimidazoles as TRPV1 antagonists were designed based on the previously reported 4,6-disubstituted benzimidazole series. The analogs were evaluated for their ability to block capsaicin- or acid-induced calcium influx in TRPV1-expressing CHO cells. These studies led to the identification of a highly potent and orally bioavailable TRPV1 antagonist, imidazole 33.

Vanilloid receptor ligands and their use in treatments

Therapeutic benzimidazoles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.